PAREXEL's ClinPhone RTSM Cuts Clinical Trial Start-Up Time - Analyst Blog

By
A A A

Global biopharmaceutical services organization, PAREXEL International Corporation ( PRXL ) launched a new version of its industry standard ClinPhone RTSM (Randomization and Trial Supply Management) solution designed to help start clinical trials more quickly. Following the announcement, shares of PAREXEL climbed 2.2% to close at $53.67 yesterday.

The latest version of the ClinPhone RTSM solution has been developed by PAREXEL Informatics - PAREXEL's wholly owned technology subsidiary, which acquired ClinPhone Plc - a clinical technology organization, in 2008.

At the start of a clinical trial, clients have to simultaneously initiate a broad range of important activities such as patient screening, enrollment and randomization, drug dispensation and supply distribution. PAREXEL's ClinPhone RTSM is incorporated with flexible, pre-built and interactive web modules that allow rapid implementation of patient, supplies and site management activities.

As part of the ClinPhone RTSM solution, its web modules provide extended functionality and place increased administrative and management control in the hands of the study teams. Integrated with the latest RTSM technology that features standardized study components for faster implementation and greater design flexibility, the study teams can start their trials more quickly.

RTSM solution is a key component of PAREXEL's proprietary Perceptive MyTrials platform, an integrated suite of applications for managing clinical trials. The leading edge solution has been used in more than 3,000 studies involving over 400,000 sites and two million patients since 1993.

PAREXEL's ClinPhone RTSM is available as a standalone solution as well as through the Perceptive MyTrials platform. ClinPhone RTSM and the Perceptive MyTrials platform are also available through the company's Perceptive Partner Program.

PAREXEL intends to meet the increasing need for conducting faster and more efficient trials by making considerable investments in developing cutting-edge technology. It is also focusing on making drug development more efficient, without compromising on patient safety or data quality.

Currently, PAREXEL has a Zacks Rank #3 (Hold). Better-ranked stocks in the medical services industry include ICON Public Limited Company ( ICLR ), BG Medicine, Inc. ( BGMD ) and Omnicare Inc. ( OCR ). While ICON Public Limited Company sports a Zacks Rank #1 (Strong Buy), both BG Medicine and Omnicare carry a Zacks Rank #2 (Buy).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

OMNICARE INC (OCR): Free Stock Analysis Report

PAREXEL INTL CP (PRXL): Free Stock Analysis Report

ICON PLC (ICLR): Free Stock Analysis Report

BG MEDICINE INC (BGMD): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: OCR , PRXL , ICLR , BGMD

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

100%
100%
100%
100%

Most Active by Volume

33,110,376
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
24,486,872
  • $7.41 ▲ 2.07%
20,864,535
  • $7.39 ▼ 2.76%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com